OMB APPROVAL
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

OMB Number: 3235-0060

Expires: July 31, 2021

Estimated average burden

hours per response..7.71

 
 
 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) 9/27/2018

 

Daxor Corporation
(Exact name of registrant as specified in its charter)

 

New York   811-22684   13-2682108
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

350 5th Avenue, New York New York   10118
(Address of principal executive offices)   (Zip Code)

 

212-330-8500
Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 

 

   

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 27, 2018 John Wilkens, Chief Financial Officer, resigned his position at Daxor Corporation to take a position in the financial services industry. On September 20, 2018, Robert J. Michel joined Daxor Corporation and assumed the role of Chief Financial Officer on September 28, 2018.

 

Item 9.01 Exhibits

 

(d) Exhibits. The following exhibit is furnished with this Current Report on Form 8-K:

 

No.   Description
     
99.1   Press Release dated September 28, 2018

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  DAXOR CORPORATION
  (Registrant)
   
Date: September 28, 2018 By: /s/ Michael Feldschuh
  Name: Michael Feldschuh
  Title: CEO & President

 

   

 

 

 

 

Exhibit 99.1

 

 

 

Daxor Corporation Appoints Robert J. Michel as

Chief Financial Officer

 

NEW YORK – September 28, 2018 - Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the appointment of Robert J. Michel, CPA, MBA as its new chief financial officer, effective September 28, 2018.

 

“Bob joins Daxor with significant experience across a wide array of industries, including serving on the board of a biometric solutions company . In addition, his public company expertise, combined with his comfort in working and communicating with the investor public make him an important addition to the Daxor team,” commented Michael Feldschuh, CEO of Daxor Corporation.

 

Mr. Michel joins Daxor with more than 30 years of experience in accounting and finance for companies specializing in consumer finance, engineering/manufacturing, marketing and the healthcare industry, both privately held and publicly traded. He most recently served as CFO of at Sher-Del Transfer and Relocation Services, and prior spent seven years as CFO of Asta Funding, a publicly traded diversified financial services company. He is a Certified Public Accountant and holds a degree in Business Administration from the Villanova School of Business and an MBA from St. John’s University.

 

“Daxor is an exciting company with the tremendous potential for growth and value creation with its game-changing technology. I look forward to supporting the Daxor team in building the business and ensuring the overall financial health of the company,” said Mr. Michel.

 

About Daxor Corporation

 

Daxor Corporation is an innovative medical instrumentation and biotechnology company. The company manufactures the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. Daxor believes that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is the company’s goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately, its mission is to help hospitals and physicians incorporate Daxor’s BVA-100 diagnostic to significantly improve the quality of patient care. For more information please visit Daxor’s website at http://www.daxor.com.

 

Forward-Looking Statements

 

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact Information:

 

Daxor Corporation:

Soren Thompson

Investor Relations

212-330-8502

sthompson@daxor.com

 

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner

CORE IR

561-479-8566

brets@coreir.com

 

Media:

Jules Abraham

CORE IR

917-885-7378

juleas@coreir.com